ANI Pharmaceuticals ANIP Rare Disease and Brands — Net Interest Expense

Other segment segments

Similar metrics at other companies

HRMYRare Neurological Diseases — Interest Expense Nonoperating

$3.23M-15.7%

HRMYRare Neurological Diseases — Net Income Loss

$32.49M-28.7%

BWINCorporate Segment and Other Operating Segment — Net Interest Expense

-$38.94M-30.4%

NMRKReportable Segment — Net Interest Expense

$6.9M-18.8%

HRMYRare Neurological Diseases — Research And Development Expense Excluding Share Based Compensation And In Process Research And Development Expense

$35.02M+8.6%

UFPTReportable Segment — Net Interest Expense

$1.74M-38.2%

Questions, answered.

What is ANI Pharmaceuticals's rare disease and brands — net interest expense?

ANI Pharmaceuticals (ANIP) reported rare disease and brands — net interest expense of $0 in Q1 2026.

What does rare disease and brands — net interest expense mean?

Represents the net cost of financing activities allocated to the segment, calculated as interest expense minus interest income. This metric reflects the segment's reliance on debt capital and its associated servicing costs.